Innovation Endeavors’ Joel Dudley on growing interest in life sciences with new fund — and why he hates ‘techbio’
Co-founded by former Google CEO Eric Schmidt, tech venture capital firm Innovation Endeavors announced a new $630 million fund Thursday — but “expect life sciences and healthcare to represent a major portion of the fund,” partner Joel Dudley told Endpoints News.
An investor in Uber and SoFi, Innovation Endeavors has been increasingly involved in the biotech space over the past few years. It has put money into companies like Eikon Therapeutics and Zymergen — which was bought by Ginkgo Bioworks in 2022 following a major implosion — and more recently, Think Bioscience and BioLoomics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.